Section Arrow
CVAC.NASDAQ
- CureVac NV
Quotes are at least 15-min delayed:2024/05/16 06:21 EDT
Last
 3.19
+0.09 (+2.90%)
Day High 
3.2888 
Prev. Close
3.1 
1-M High
3.155 
Volume 
515.23K 
Bid
3.19
Ask
3.23
Day Low
3.1 
Open
3.13 
1-M Low
2.215 
Market Cap 
695.35M 
Currency USD 
P/E -- 
%Yield
10-SMA 2.93 
20-SMA 2.7 
50-SMA 2.93 
52-W High 12.36 
52-W Low 2.215 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.18/-0.61
Enterprise Value
732.17M
Balance Sheet
Book Value Per Share
2.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
53.76M
Operating Revenue Per Share
0.18
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 06:21 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac's first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipelinecandidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.